190 related articles for article (PubMed ID: 11744411)
1. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab.
Brock MV; Borja MC; Ferber L; Orens JB; Anzcek RA; Krishnan J; Yang SC; Conte JV
J Heart Lung Transplant; 2001 Dec; 20(12):1282-90. PubMed ID: 11744411
[TBL] [Abstract][Full Text] [Related]
2. Induction therapy in lung transplantation: initial single-center experience comparing daclizumab and antithymocyte globulin.
Lischke R; Simonek J; Davidová R; Schützner J; Stolz AJ; Vojácek J; Burkert J; Pafko P
Transplant Proc; 2007; 39(1):205-12. PubMed ID: 17275507
[TBL] [Abstract][Full Text] [Related]
3. Effects of induction immunosuppression regimen on acute rejection, bronchiolitis obliterans, and survival after lung transplantation.
Ailawadi G; Smith PW; Oka T; Wang H; Kozower BD; Daniel TM; Kron IL; Jones DR
J Thorac Cardiovasc Surg; 2008 Mar; 135(3):594-602. PubMed ID: 18329476
[TBL] [Abstract][Full Text] [Related]
4. The incidence of acute cellular rejection after lung transplantation: a comparative study of anti-thymocyte globulin and daclizumab.
Burton CM; Andersen CB; Jensen AS; Iversen M; Milman N; Boesgaard S; Arendrup H; Eliasen K; Carlsen J
J Heart Lung Transplant; 2006 Jun; 25(6):638-47. PubMed ID: 16730569
[TBL] [Abstract][Full Text] [Related]
5. Induction therapy for pediatric and adult heart transplantation: comparison between OKT3 and daclizumab.
Chin C; Pittson S; Luikart H; Bernstein D; Robbins R; Reitz B; Oyer P; Valantine H
Transplantation; 2005 Aug; 80(4):477-81. PubMed ID: 16123721
[TBL] [Abstract][Full Text] [Related]
6. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.
Nashan B; Light S; Hardie IR; Lin A; Johnson JR
Transplantation; 1999 Jan; 67(1):110-5. PubMed ID: 9921806
[TBL] [Abstract][Full Text] [Related]
7. Comparison of daclizumab, an interleukin 2 receptor antibody, to anti-thymocyte globulin-Fresenius induction therapy in kidney transplantation.
Abou-Jaoude MM; Ghantous I; Almawi WY
Mol Immunol; 2003 Jul; 39(17-18):1083-8. PubMed ID: 12835081
[TBL] [Abstract][Full Text] [Related]
8. Antibody induction therapy for lung transplant recipients.
Penninga L; Møller CH; Penninga EI; Iversen M; Gluud C; Steinbrüchel DA
Cochrane Database Syst Rev; 2013 Nov; 2013(11):CD008927. PubMed ID: 24282128
[TBL] [Abstract][Full Text] [Related]
9. Five-year outcomes with alemtuzumab induction after lung transplantation.
Shyu S; Dew MA; Pilewski JM; DeVito Dabbs AJ; Zaldonis DB; Studer SM; Crespo MM; Toyoda Y; Bermudez CA; McCurry KR
J Heart Lung Transplant; 2011 Jul; 30(7):743-54. PubMed ID: 21420318
[TBL] [Abstract][Full Text] [Related]
10. A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients.
Mariat C; Alamartine E; Diab N; de Filippis JP; Laurent B; Berthoux F
Transpl Int; 1998; 11(3):231-6. PubMed ID: 9638854
[TBL] [Abstract][Full Text] [Related]
11. Induction therapy after cardiac transplantation: a comparison of anti-thymocyte globulin and daclizumab in the prevention of acute rejection.
Carlsen J; Johansen M; Boesgaard S; Andersen CB; Arendrup H; Aldershvilet J; Mortensen SA
J Heart Lung Transplant; 2005 Mar; 24(3):296-302. PubMed ID: 15737756
[TBL] [Abstract][Full Text] [Related]
12. Induction antibody therapy in renal transplantation using early steroid withdrawal: long-term results comparing anti-IL2 receptor and anti-thymocyte globulin.
Libório AB; Mendoza TR; Esmeraldo RM; Oliveira ML; Paes FJ; Silva Junior GB; Daher EF
Int Immunopharmacol; 2011 Nov; 11(11):1832-6. PubMed ID: 21835269
[TBL] [Abstract][Full Text] [Related]
13. Induction immunosuppression for lung transplantation with OKT3.
Wain JC; Wright CD; Ryan DP; Zorb SL; Mathisen DJ; Ginns LC
Ann Thorac Surg; 1999 Jan; 67(1):187-93. PubMed ID: 10086547
[TBL] [Abstract][Full Text] [Related]
14. Experience with single-dose daclizumab in the prevention of acute rejection in heart transplantation.
Cuppoletti A; Perez-Villa F; Vallejos I; Roig E
Transplant Proc; 2005 Nov; 37(9):4036-8. PubMed ID: 16386620
[TBL] [Abstract][Full Text] [Related]
15. Tacrolimus: a superior agent to OKT3 for treating cases of persistent rejection after intrathoracic transplantation.
Meiser BM; Uberfuhr P; Fuchs A; Schulze C; Nollert G; Mair H; Martin S; Pfeiffer M; Reichenspurner H; Kreuzer E; Reichart B
J Heart Lung Transplant; 1997 Aug; 16(8):795-800. PubMed ID: 9286771
[TBL] [Abstract][Full Text] [Related]
16. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function.
Emre S; Gondolesi G; Polat K; Ben-Haim M; Artis T; Fishbein TM; Sheiner PA; Kim-Schluger L; Schwartz ME; Miller CM
Liver Transpl; 2001 Mar; 7(3):220-5. PubMed ID: 11244163
[TBL] [Abstract][Full Text] [Related]
17. Rabbit antithymocyte globulin versus OKT3 induction therapy after heart-lung and lung transplantation: effect on survival, rejection, infection, and obliterative bronchiolitis.
Barlow CW; Moon MR; Green GR; Gamberg P; Theodore J; Reitz BA; Robbins RC
Transpl Int; 2001 Aug; 14(4):234-9. PubMed ID: 11512056
[TBL] [Abstract][Full Text] [Related]
18. Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients.
Huurman VA; Kalpoe JS; van de Linde P; Vaessen N; Ringers J; Kroes AC; Roep BO; De Fijter JW
Diabetes Care; 2006 Apr; 29(4):842-7. PubMed ID: 16567825
[TBL] [Abstract][Full Text] [Related]
19. Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation.
Pilch NA; Taber DJ; Moussa O; Thomas B; Denmark S; Meadows HB; McGillicuddy JW; Srinivas TR; Baliga PK; Chavin KD
Ann Surg; 2014 May; 259(5):888-93. PubMed ID: 24513787
[TBL] [Abstract][Full Text] [Related]
20. Delayed onset of cardiac allograft vasculopathy by induction therapy using anti-thymocyte globulin.
Zhang R; Haverich A; Strüber M; Simon A; Bara C
J Heart Lung Transplant; 2008 Jun; 27(6):603-9. PubMed ID: 18503958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
